 Pfizer says it will continue to develop the once-daily version of its weight-loss pill after it saw encouraging data in an early-stage trial. The company plans to conduct studies in the second half of the year evaluating multiple doses of that drug. The pharmaceutical giant in December discontinued a twice-daily version of the medication after patients had trouble tolerating the drug in a mid-stage trial.